Progyny Inc
PGNY
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
174.6% upsideUndervalued by 174.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.04 Billion |
|---|---|
| Enterprise Value | $1.93 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.68 |
| Beta | 1.04 |
| Outstanding Shares | 80,920,993 |
Return
| Return on Equity | 15.41% |
|---|---|
| Return on Assets | 9.69% |
| Return on Invested Capital | 22.01% |
Valuation & Multiples
| P/E Ratio | 31.18 |
|---|---|
| PEG | 51.18 |
| Price to Sales | 1.78 |
| Price to Book Ratio | 5.33 |
| Enterprise Value to Revenue | 1.5 |
| Enterprise Value to EBIT | 19 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4963▲ 26.74% |
|---|---|
| Total Calls | 67,900▼ 2.86% |
| Total Puts | 33,700▲ 110.63% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.12%▲ 0.78% |
|---|---|
| Total Invested | $1.37B▼ 33.63% |
| Investors Holding | 295▼ 22.00% |
ESG Score
No data
About Progyny Inc
Relevant Senate Committees
This committee directly influences corporate tax structures and the tax treatment of benefits, impacting Progyny's financial performance and the attractiveness of employer-sponsored health benefits that Progyny manages.
This committee controls taxation and entitlement spending. Tax policy regarding employer-sponsored benefits and corporate taxation directly impacts Progyny's profitability and the demand for its services, while broad healthcare policy changes also affect its market.
This committee directly regulates health policy, labor laws, and aspects of the FDA. As a benefits management company, Progyny is highly susceptible to changes in employer-sponsored benefits regulations, healthcare mandates, and oversight of fertility-related drugs/devices.